Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome
Open accessThe DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in sex hormones levels may lead to microbial dysbiosis which has been previously implicated in IBD and its symptom severity.(40)”
From Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity—A Systematic Review (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–267 of 267
Hilsden, R. J., Verhoef, M. J., Best, A., & Pocobelli, G. S. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07519.x · Cited by 129 · cited 1×
“6% of the Canadian prior CAM users had experienced potential adverse effects [197].”
BackgroundHenker, J., Muller, S., Laass, M., Schreiner, A., & Schulze, J. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027463 · Cited by 128 · cited 1×
“The most commonly evaluated single probiotic strains that have been reported to be effective and as safe as mesalazine for the maintenance of remission in active UC patients are Lactobacillus GG [237,238], Escherichia coli Nissle 1917 [239,240], Bifidobacteria [241], and the yeast strain Saccharomyces boulardii [242].”
BackgroundLanghorst, J., Anthonisen, I. B., Steder-Neukamm, U., Lüdtke, R., Spahn, G., Michalsen, A., & Dobos, G. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000160771.71328.6c · Cited by 127 · cited 1×
“Among the Canadian population, herbal medicine therapies were the most common, accounting for 41% of CAM users [196], and only 1.”
BackgroundReal-Time Analysis of Mucosal Flora in Patients with Inflammatory Bowel Disease in India
Verma, R., Verma, A. K., Ahuja, V., & Paul, J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01360-10 · Cited by 124 · cited 1×
“Human Bacteroides, Lactobacillus, Ruminococcus, and Bifidobacterium Peptostreptococcus, Campylobacter, Methanobrevibacter Decrease Increase [158]”
BackgroundThe role of infection in the aetiology of inflammatory bowel disease
Hansen, R., Thomson, J. M., El-Omar, E. M., & Hold, G. L. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-009-0191-y · Cited by 121 · cited 1×
“Similarly, the demonstration of MAP persistence in macrophages of mice deficient in the autophagy ATG16L1 gene proved the role of MAP in intestinal inflammation [134,135].”
BackgroundYang, I., Eibach, D., Kops, F., Brenneke, B., Woltemate, S., Schulze, J., Bleich, A., Gruber, A. D., Muthupalani, S., Fox, J. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070783 · Cited by 120
Metabolic and Intestinal Effects of Short‐Chain Fatty Acids
Rombeau, J. L., & Kripke, S. A. (1990) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860719001400507 · Cited by 118 · cited 1×
“Fermentation products such as acetic, propionic, and butyric acids of carbohydrates are involved in the activation and regulation of multiple colon-specific and systemic pathways [210].”
BackgroundSetoyama, H., Imaoka, A., Ishikawa, H., & Umesaki, Y. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(02)00080-1 · Cited by 114 · cited 1×
“Similarly, other studies have investigated the efficacy of fructooligosaccharides (FOS) and have shown a significant increase in the butyrate level [218], and an increase of beneficial bacteria in CD patients and a TNBS-induced colitis model of rats [224,225].”
BackgroundUse of antibiotics in the treatment of inflammatory bowel disease
Perencevich, M. L., & Burakoff, R. B. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000225330.38119.c7 · Cited by 108
Shiba, T., Aiba, Y., Ishikawa, H., Ushiyama, A., Takagi, A., Mine, T., & Koga, Y. (2003) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2003.tb03368.x · Cited by 106 · cited 2×
“Abbreviations IBD, Inflammatory Bowel Disease; CAM, complementary and alternative medicine; CD, Crohn’s disease; DAI, disease activity index; TNBS, trinitrobenzene sulfonic acid; UC, ulcerative colitis; SCFAs, short-chain fatty acids; SFB, segmented filamentous bacteria; IL, interleukin; CRP, C reactive protein, HM, h…”
BackgroundManagement consensus of inflammatory bowel disease for the Asia–Pacific region
Ouyang, Q., Tandon, R. K., Goh, K., Pan, G., Fock, K. M., Fiocchi, C., Lam, S., & Xiao, S. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04674.x · Cited by 106 · cited 1×
“4 cases per 100,000 persons per year, respectively [9].”
BackgroundLong-term Follow-up of Ulcerative Colitis in the Chinese Population
Chow, D. K., Leong, R. W. L., Tsoi, K. K. F., Ng, S. S. M., Leung, W. K., Wu, J. C., Wong, V. W., Chan, F. K. L., & Sung, J. J. �. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.74 · Cited by 105 · cited 1×
“public health challenge [3], and the frequency of incidence is progressively increasing across the globe [4,5].”
BackgroundThe Role of Bacteria in the Pathogenesis of Inflammatory Bowel Disease
Friswell, M. K., Campbell, B. J., & Rhodes, J. M. (2010) · Gut and Liver · doi:10.5009/gnl.2010.4.3.295 · Cited by 105 · cited 1×
“Moreover, engagement of MAP in IBD pathology has been supported by the presence of antibodies and reactive T-cells against MAP in CD patients [131].”
BackgroundImmune dysregulation in the functional gastrointestinal disorders
Keely, S., Walker, M. M., Marks, E., & Talley, N. J. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12548 · Cited by 104
Navaneethan, U. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i39.4892 · Cited by 97
Mycobacterium avium subspecies paratuberculosis in children with early-onset Crohnʼs disease
Kirkwood, C. D., Wagner, J., Boniface, K., Vaughan, J., Michalski, W. P., Catto-Smith, A. G., Cameron, D. J. S., & Bishop, R. F. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20967 · Cited by 96
Bengmark, S. (2001) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200111000-00019 · Cited by 96 · cited 3×
“Synbiotics are combined pro- and prebiotics that can confer a mutual synergistic beneficial effect on host health [112,241].”
BackgroundEvidence for the involvement of infectious agents in the pathogenesis of Crohn’s disease
Hertogh, G. D. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.845 · Cited by 94 · cited 1×
“maltophilia, Klebsiella, Salmonella Increase [149]”
Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences
Serino, M., Blasco-Baque, V., Nicolas, S., & Burcelin, R. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0540-1 · Cited by 93
Mechanisms of Microbe–Host Interaction in Crohn’s Disease: Dysbiosis vs. Pathobiont Selection
Buttó, L. F., Schaubeck, M., & Haller, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00555 · Cited by 93 · cited 2×
“associated with a variety of gut pathologies [49] and intestinal inflammation [50].”
BackgroundProbiotics in the Treatment of Inflammatory Bowel Disease
Rioux, K. P., & Fedorak, R. N. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200603000-00019 · Cited by 90 · cited 1×
“Moreover, in order to predict the role of gut microbiota in the intestinal inflammation of IBD, an alternative strategy was applied in many studies in which the gut microbiota was targeted, and the results suggested that altered gut microbiota is key to the induction and maintenance of colon inflammation [109,110].”
Methodvan Dieren, J. M., Kuipers, E. J., Samsom, J. N., Nieuwenhuis, E. E. S., & van der Woude, J. C. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000209787.19952.53 · Cited by 87 · cited 1×
“Commonly recommended standard therapies for IBD-UC patients are corticosteroids [17], amino-salicylates [18,19], and immunosuppressive agents [20,21].”
BackgroundEffects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats
Kanauchi, O., Nakamura, T., Agata, K., Mitsuyama, K., & Iwanaga, T. (1998) · Journal of Gastroenterology · doi:10.1007/s005350050067 · Cited by 87 · cited 1×
“GBF improved the Disease Activity Index (DAI) by elevating the growth of protective bacteria like Bifidobacterium and Eubacterium [218,219] and the fecal butyrate level [220], and by lowering the serum level of CRP [221] and pro-inflammatory cytokines IL-6 and IL-8, along with the suppression of mast cells in UC patie…”
BackgroundKanamori, Y., Hashizume, K., Sugiyama, M., Morotomi, M., & Yuki, N. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1010611920750 · Cited by 85 · cited 1×
“breve, Lactobacillus casei, and galactooligosaccharides [255].”
Zhang, M., Liu, B., Zhang, Y., Wei, H., Lei, Y., & Zhao, L. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01720-06 · Cited by 83
Pierce, E. S. (2010) · Gut Pathogens · doi:10.1186/1757-4749-2-21 · Cited by 82
Kanauchi, O., & Agata, K. (1997) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.61.29 · Cited by 80 · cited 1×
“The most investigated prebiotic is germinated barley foodstuff (GBF), which is rich in glutamine and hemicellulose as its main components [217] and has shown a significantly effective role in patients with mild-to-moderate UC [218].”
BackgroundGastrointestinal infection as a trigger for inflammatory bowel disease
Mann, E. A., & Saeed, S. A. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834c453e · Cited by 79 · cited 2×
“Furthermore, the existence of AIEC in healthy individuals shows that AIEC is a normal gut flora member, and acts as an opportunistic pathogen in a genetically susceptible host in a way that either causes or contributes to disease pathogenesis [125].”
BackgroundProgression of inflammatory bowel disease in China
WANG, Y. F., OUYANG, Q., & HU, R. W. (2010) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00421.x · Cited by 79 · cited 1×
“public health challenge [3], and the frequency of incidence is progressively increasing across the globe [4,5].”
BackgroundComplementary and alternative medicine use by patients with inflammatory bowel disease
Bensoussan, M., Jovenin, N., Garcia, B., Vandromme, L., Jolly, D., Bouché, O., Thiéfin, G., & Cadiot, G. (2006) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(06)73072-x · Cited by 77 · cited 1×
“3%) have had experience with CAM, while in Canada, of 2847 IBD patients, 47% had experienced CAM therapies [195].”
BackgroundCampylobacter concisusand inflammatory bowel disease
Zhang, L., Lee, H., Grimm, M. C., Riordan, S. M., Day, A. S., & Lemberg, D. A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i5.1259 · Cited by 77 · cited 1×
“coli and non-jejuni Campylobacter) Increase [147,148]”
Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients
Matijašić, M., Meštrović, T., Perić, M., Paljetak, H. Č., Panek, M., Bender, D. V., Kelečić, D. L., Krznarić, Ž., & Verbanac, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040578 · Cited by 76 · cited 2×
“Therefore, scientists interested in the use of a mutually supportive combination of pre and probiotics in the form of synbiotics have begun to pursue a solution [116], however more in-depth studies are required to develop a universally effective study protocol for the evaluation of prebiotics in IBD clinical and labor…”
BackgroundKanauchi, O., Matsumoto, Y., Matsumura, M., Fukuoka, M., & Bamba, T. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381675 · Cited by 73
Homeostatic Effects of TLR9 Signaling in Experimental Colitis
Lee, J., Rachmilewitz, D., & Raz, E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1326.022 · Cited by 72
Matsumoto, S., Watanabe, N., Imaoka, A., & Okabe, Y. (2001) · Digestion · doi:10.1159/000048846 · Cited by 72 · cited 1×
“Oligo-fructose-enriched inulin has shown a decrease in fecal calprotectin in UC patients, indicating a reduction in inflammation [226].”
BackgroundJuste, R. A., Elguezábal, N., Garrido, J. M., Pavón, A., Geijó, M., Sevilla, I. A., Cabriada, J. L., Tejada, A., García-Campos, F., Casado, R., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002537 · Cited by 70 · cited 1×
“For example, two different studies have reported a higher level of MAP-DNA in healthy volunteers than in IBD-diseased cases [130,136].”
ResultNovel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity
Habens, F., Srinivasan, N., Oakley, F., Mann, D. A., Ganesan, A., & Packham, G. (2005) · APOPTOSIS · doi:10.1007/s10495-005-1877-0 · Cited by 69 · cited 1×
“Commonly recommended standard therapies for IBD-UC patients are corticosteroids [17], amino-salicylates [18,19], and immunosuppressive agents [20,21].”
BackgroundKanauchi, O., Iwanaga, T., Andoh, A., Araki, Y., Nakamura, T., Mitsuyama, K., Suzuki, A., Hibi, T., & Bamba, T. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02427.x · Cited by 69 · cited 3×
“More in-depth studies conducted in UC and CD patients have shown a clear reduction in Firmicutes (especially Clostridium groups) and an increase in Proteobacteria [28,84,85], alongside a significant decrease of many other beneficial bacterial species from the genera Bacteriodes, Lactobacillus, and Eubacterium [86,87].”
BackgroundBerg, D., Clemente, J. C., & Colombel, J.-F. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1013031 · Cited by 64 · cited 1×
“other metabolic disorders has been investigated in many animal studies, and has found particular success in patients suffering from severe relapsing Clostridium difficile infection [256].”
ResultLaake, K. O., Line, P. D., Aabakken, L., Løtveit, T., Bakka, A., Eide, J., Røsetti, A., Grzyb, K., Bjørneklett, A., & Vatn, M. H. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310000906 · Cited by 64 · cited 1×
“longum and psyllium, both used in a randomized control trial as a supplement to conventional therapy in UC patients, showed a good synergistic effect and improved the disease clinical activity index compared to a probiotic or prebiotic alone [251,252].”
ResultJuvenile ferric iron prevents microbiota dysbiosis and colitis in adult rodents
Ettreiki, C., Gadonna‐Widehem, P., Mangin, I., Coëffier, M., Delayre‐Orthez, C., & Anton, P. M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i21.2619 · Cited by 63 · cited 1×
“TNBS colitis Enterobacteriaceae, Bacteroides Increase [167]”
Kim, H., Rhee, S. H., Pothoulakis, C., & LaMont, J. T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.06.063 · Cited by 63
Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease
Wu, W. H., Chen, F., Liu, Z., & Cong, Y. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000775 · Cited by 59
Nerstedt, A., Nilsson, E. C., Ohlson, K., Håkansson, J., Thomas Svensson, L., Löwenadler, B., Svensson, U. K., & Mahlapuu, M. (2007) · British Journal of Nutrition · doi:10.1017/s0007114507682907 · Cited by 56
Pils, M. C., Bleich, A., Prinz, I., Fasnacht, N., Bollati-Fogolin, M., Schippers, A., Rozell, B., & Müller, W. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21587 · Cited by 53
Araki, Y., Andoh, A., Koyama, S., Fujiyama, Y., Kanauchi, O., & Bamba, T. (2000) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.64.1794 · Cited by 53 · cited 1×
“GBF improved the Disease Activity Index (DAI) by elevating the growth of protective bacteria like Bifidobacterium and Eubacterium [218,219] and the fecal butyrate level [220], and by lowering the serum level of CRP [221] and pro-inflammatory cytokines IL-6 and IL-8, along with the suppression of mast cells in UC patie…”
BackgroundWillot, S., Noble, A., & Deslandres, C. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21653 · Cited by 53 · cited 1×
“Commonly recommended standard therapies for IBD-UC patients are corticosteroids [17], amino-salicylates [18,19], and immunosuppressive agents [20,21].”
BackgroundAnalysis of Gut Microbiome and Diet Modification in Patients with Crohn’s Disease
Walters, S. S. (2014) · SOJ Microbiology & Infectious Diseases · doi:10.15226/sojmid/2/3/00122 · Cited by 53 · cited 1×
“, Bacteroides Bacteroides fragilis, proteobacteria Decrease Increase [154]”
BackgroundLactobacillus paracasei subsp. paracasei B21060 Suppresses Human T-Cell Proliferation
Peluso, I., Fina, D., Caruso, R., Stolfi, C., Caprioli, F., Fantini, M. C., Caspani, G., Grossi, E., Di Iorio, L., Paone, F. M., et al. (2007) · Infection and Immunity · doi:10.1128/iai.01172-06 · Cited by 48
Navigating the Microbiota Seas: Triangulation Finds a Way Forward
Rosen, C. E., & Palm, N. W. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.015 · Cited by 40
Saccharomyces boulardii Plus Rifaximin in Mesalamine-intolerant Ulcerative Colitis
Guslandi, M. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181cb4233 · Cited by 39 · cited 1×
“The most commonly evaluated single probiotic strains that have been reported to be effective and as safe as mesalazine for the maintenance of remission in active UC patients are Lactobacillus GG [237,238], Escherichia coli Nissle 1917 [239,240], Bifidobacteria [241], and the yeast strain Saccharomyces boulardii [242].”
BackgroundElguezábal, N., Chamorro, S., Molina, E., Garrido, J. M., Izeta, A., Rodrigo, L., & Juste, R. A. (2012) · Gut Pathogens · doi:10.1186/1757-4749-4-6 · Cited by 37 · cited 1×
“MAP-induced intestinal inflammation in cattle is termed Johne’s disease, and it almost mimics the clinical and histological features of human CD [127].”
BackgroundFoster, A., & Jacobson, K. (2013) · Frontiers in Pediatrics · doi:10.3389/fped.2013.00034 · Cited by 36
Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4+T Cells
Zou, Y., Li, W., Wan, Z., Zhao, B. T., He, Z., Wu, Z., Huang, G., Wang, J., Li, B., Lu, Y.-J., et al. (2015) · BioMed Research International · doi:10.1155/2015/102021 · Cited by 35
Bartels, L. E., Jepsen, P., Christensen, L. A., Gerdes, L. U., Vilstrup, H., & Dahlerup, J. F. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv229 · Cited by 30
What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease?
Cary, V. A., & Boullata, J. I. (2010) · Journal of Clinical Nursing · doi:10.1111/j.1365-2702.2009.03123.x · Cited by 29
Bioecological control of inflammatory bowel disease
Bengmark, S. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2006.10.001 · Cited by 29 · cited 1×
“Moreover, in order to predict the role of gut microbiota in the intestinal inflammation of IBD, an alternative strategy was applied in many studies in which the gut microbiota was targeted, and the results suggested that altered gut microbiota is key to the induction and maintenance of colon inflammation [109,110].”
MethodMicrobial Learning Lessons: SFB Educate the Immune System
Lee, Y. K., & Mazmanian, S. K. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.002 · Cited by 28
IL-17–targeting biologics aim to become standard of care in psoriasis
Ratner, M. (2015) · Nature Biotechnology · doi:10.1038/nbt0115-3 · Cited by 27 · cited 1×
“In addition, biological agents such as infliximab and tacrolimus [22] have been used as part of the regime for UC since 1998 and 2006, respectively [23].”
Moss, A. C., & Nanda (2012) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s26556 · Cited by 27
Bugs and Drugs: Insights into the Pathogenesis of Inflammatory Bowel Disease
Nguyen, G. C. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.308 · Cited by 23
Expressing the Differences between Crohn Disease and Ulcerative Colitis
Wijmenga, C. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020230 · Cited by 21 · cited 1×
“IBD has two major clinical forms, ulcerative colitis (UC) and Crohn’s disease (CD), which are differentiated by the different clinical manifestations of inflammation and intestinal localization [1,2].”
Refractory ulcerative colitis treatment.
MacDermott, R. P., & Green, J. A. (2007) · PubMed Central · Cited by 16
Current roles of specific bacteria in the pathogenesis of inflammatory bowel disease
McMullen, L., Leach, S. T., Lemberg, D. A., & Day, A. S. (2015) · AIMS Microbiology · doi:10.3934/microbiol.2015.1.82 · Cited by 6 · cited 1×
“Human Mycobacterial species (MAP) Increase [146]”
McCarthy, J., Sheil, B., O’Mahony, L., Bennett, M., Ryan, P., Fitzgibbon, J., Kiely, B., Collins, J., & Shanahan, F. (2004) · Endoscopy · doi:10.1055/s-2004-824988 · Cited by 6
Sun, L. (2013) · Weiliang yuansu yu jiankang yanjiu · Cited by 5
Zhen, Z. (2014) · Zhongguo weishengtaixue zazhi · Cited by 3
Research works printed but not linked: 2
- Zhang, 2007, Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis, Mod. J. Integr. Tradit. West. Med., 16, 5156
- Yan, 2013, Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats, Chin. Pharmacol. Bull., 29, 1275
Cited by
Postbiotics—A Step Beyond Pre- and Probiotics
Żółkiewicz, J., Marzec, A., Ruszczyński, M., & Feleszko, W. (2020) · Nutrients · doi:10.3390/nu12082189 · Cited by 784
Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues
Lee, M., & Chang, E. B. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.056 · Cited by 645
Gut microbiota and Covid-19- possible link and implications
Dhar, D., & Mohanty, A. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198018 · Cited by 608
Kumar Singh, A., Cabral, C., Kumar, R., Ganguly, R., Kumar Rana, H., Gupta, A., Rosaria Lauro, M., Carbone, C., Reis, F., & Pandey, A. K. (2019) · Nutrients · doi:10.3390/nu11092216 · Cited by 433
Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation
Akhtar, M., Chen, Y., Ma, Z., Zhang, X., Shi, D., Khan, J. A., & Liu, H. (2022) · Animal Nutrition · doi:10.1016/j.aninu.2021.11.005 · Cited by 363
Metadata
- Authors
- Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C.
- Affiliations
- Lanzhou University (CN)
- Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis, Lanzhou 730000, China
- Corresponding author
- Zhang, Chunjiang
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2019-08-13
- Volume
- 8
- Issue
- 3
- Pages
- 126
- ISSN
- 2076-0817 (ISSN-L)
- PMC
- PMC6789542
- OpenAlex
- W2966933380
- Cited by
- 771
- References
- 267
- Citations by year
- 2026: 43 · 2025: 105 · 2024: 149 · 2023: 134 · 2022: 135 · 2021: 132 · 2020: 66 · 2019: 7
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Jiangsu Science and Technology Major Project ((No. BA2016036))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- inflammatory bowel disease, gut microbiota, dysbiosis, Crohn's disease, ulcerative colitis, intestinal inflammation, microbiota-based therapy, probiotics, prebiotics, mouse colitis model, IBD pathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.